TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01006122

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-03654746
Description: Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
Study: NCT01110551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (SC)
Description: Phosphate buffered saline administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (ID)
Description: Phosphate buffered saline administered intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (ID)
Description: Phosphate buffered saline administered intradermally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Live Tetravalent Chimeric Dengue Vaccine (SC)
Description: DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.
Study: NCT03027635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PleurX, peritoneal tunnelated catheter
Description: A permanent catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Large Volume Paracentesis
Description: Short time drainage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 500Mg Tablet
Description: SBP prophylaxis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500Mg Tablet
Description: SBP prophylaxis
Study: NCT02146937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide plus Finasteride- Combination therapy
Description: 3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
Study: NCT03552978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tech-Facilitated IC Intervention
Description: The Integrated Care (IC) treatment protocol for smoking cessation is a PTSD-informed intervention that has been adapted to be delivered over video or telephone and to incorporate technological components, including the Stay Quit Coach (SQC) smart phone application (app) which is a public domain, no-cost mobile app designed to complement the IC protocol with evidence-based tools to support smoking cessation. and the coVita Bedfont® Scientific Ltd iCO® Smokerlyzer® device and app which is a mobile carbon monoxide (CO) monitor that provides CO readings in order to self-monitor progress in quitting. The coVita mobile app is compatible with iOS \&Android and used with the iCO® Smokerlyzer® to display CO readings. Content of sessions is consistent with that delivered in the IC treatment protocol for veteran smokers with post-traumatic stress disorder (PTSD).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Quitline
Description: The SFVAMC's standard of care referral service, known as the VA Quitline which involves weekly telephone sessions through the VA's proactive telephone Quitline, available to all veterans for up to 8 weeks.
Study: NCT03385187

Intervention type: DEVICE
Group type: OTHER
Intervention: NightOwl HSAT
Description: Patient wears the NightOwl sensor device
Study: NCT01244815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
Study: NCT01110551

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Live Tetravalent Chimeric Dengue Vaccine (SC)
Description: DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Description: DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Description: DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10\^3, D2: 5 x 10\^3, D3: 1 x 10\^4, and D4: 2 x 10\^5, total virus dose \[plaque forming units (PFU)\]: 2.2 x 10\^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10\^4, D2: 5 x 10\^4, D3: 1 x 10\^5, and D4: 3 x 10\^5, total virus dose (PFU): 4.7 x 10\^5. DENVax administered intradermally.
Study: NCT01244815

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match asenapine
Description: Placebo tablets to match asenapine tablets, administered sublingually twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study: NCT04362592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In Utero Endoscopic Correction of Myelomeningocele IDE - Percutaneous Technique
Description: The percutaneous approach uses endoscopes through a closed maternal abdomen and closed uterus to perform the spina bifida correction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In Utero Endoscopic Correction of Myelomeningocele IDE - Laparotomy/Uterine Exteriorization Technique
Description: The laparotomy/uterine exteriorization technique uses endoscopes through an open abdomen and closed, exteriorized uterus to perform the spina bifida correction.
Study: NCT03411031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab according to dosing schedule outlined in treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab according to dosing schedule outlined in treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide according to dosing schedule outlined in treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide according to dosing schedule outlined in treatment arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is a commercially available drug. The description, how supplied, and storage instructions for dexamethasone product are found in the prescribing information.~During the study, dexamethasone will be administered as premedication for elotuzumab as indicated in the package insert.
Study: NCT00536939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzastaurin
Description: 1125 milligrams (mg) loading dose on Day 1 of Cycle 1 only then 500 mg oral once daily, until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bevacizumab
Description: 10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 milligrams per kilogram (mg/kg) intravenously, Days 1 and 15 every 28 days, until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 90 milligrams per square meter (mg/m\^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression
Study: NCT01461161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bardoxolone methyl
Description: oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bardoxolone methyl
Description: oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bardoxolone methyl
Description: oral, single dose
Study: NCT04393779

Intervention type: DEVICE
Group type: OTHER
Intervention: HARPOON Beating Heart Mitral Valve Repair System (MVRS)
Description: Repair of the chordae tendinae in the mitral valve.
Study: NCT01622088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Oral tablet 150 mg given twice daily (BID)
Study: NCT04485793

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement
Description: Dietary supplement formulated with 400 mg Bergamot d.e. obtained from different parts of the Citrus Bergamot whole fruit (Citrus bergamia Risso et Poiteau, fructus), specifically from fresh fruits collected from November to February (Brumex TM).~Oral administration: 1 tablet/day at evening meal
Study: NCT01244815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
Study: NCT01909583

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: STAGES-Booklet
Description: STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
Study: NCT00536939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 milligrams per square meter (mg/m\^2), intravenously, Days 1 ,8, and 15 every 28 days until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, daily, until disease progression
Study: NCT01984333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online cognitive training
Description: Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
Study: NCT00736697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxidectin
Study: NCT01909583

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STAGES-Booklet
Description: STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
Study: NCT01527825

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (seasonal)
Description: Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (seasonal)
Description: Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (seasonal)
Description: Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:~* An A/California/7/2009 (H1N1)pdm-like virus~* An A/Perth/16/2009 (H3N2)-like virus\*~* A B/Brisbane/60/2008-like virus \* A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: 0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: 0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
Study: NCT04485793

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration: 1 tablet/day at evening meal
Study: NCT00396721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor + statin
Description: sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus (study drug)+ACE inhibitor + statin
Description: enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
Study: NCT02592694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocktail
Description: Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thrombus aspiration
Description: manual thrombus aspiration

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thrombus aspiration
Description: manual thrombus aspiration
Study: NCT02529657

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low Level Laser Therapy
Description: In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
Study: NCT00763984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bladder Health class
Description: Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
Study: NCT04579497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 38°C warm water footbath
Description: A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 38°C, followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 40°C warm water footbath
Description: A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 40°C, followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 42°C warm water footbath
Description: A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water at a constant temperature of 42°C, followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 38-42°C rising temperature footbath
Description: A ten-minute pre-intervention rest period followed by a 30-minute footbath with 16 l of warm water. Water temperature starts at 38°C and is increased by 1°C every 6 minutes, resulting in 42°C after 30 minutes. The footbath is followed by a ten-minute post-intervention rest period.
Study: NCT03180034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03121781

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory support- interface
Description: change interface to RAM cannula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory support- interface
Description: change interface to binasal prongs
Study: NCT03180034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Papillomavirus Bivalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM